Citrus auraptene: A potential multifunctional therapeutic agent for nonalcoholic fatty liver disease

Autor: Sahebkar Amirhossein

Fragmento

Dear Editor Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease that encompasses a range of disorders from simple steatosis to cirrhosis and hepatocellular carcinoma. Although the pathophysiology of NAFLD has not been fully clarified, the “two-hit” hypothesis is currently regarded as the most widely accepted etiopathophysiologic model for this disorder. According to this model, hepatic insulin resistance and consequent fat accumulation in hepatocytes represent the first hit (hepatic steatosis), which may predispose to hepatic injury and non-alcoholic steatohepatitis (NASH) in the second hit. Oxidative stress has been proposed as the primary mediator of the second hit.1 In spite of its high prevalence, there is as yet no proven treatment for NAFLD.

Palabras clave:

2011-09-14   |   1,024 visitas   |   Evalua este artículo 0 valoraciones

Vol. 10 Núm.4. Octubre-Diciembre 2011 Pags. 575-577 Ann Hepatol 2011; 10(4)